[go: up one dir, main page]

PE20231308A1 - Proceso e intermedios para preparar un inhibidor de jak1 - Google Patents

Proceso e intermedios para preparar un inhibidor de jak1

Info

Publication number
PE20231308A1
PE20231308A1 PE2023000303A PE2023000303A PE20231308A1 PE 20231308 A1 PE20231308 A1 PE 20231308A1 PE 2023000303 A PE2023000303 A PE 2023000303A PE 2023000303 A PE2023000303 A PE 2023000303A PE 20231308 A1 PE20231308 A1 PE 20231308A1
Authority
PE
Peru
Prior art keywords
salt
formula
prepare
jak1 inhibitor
itacitinib
Prior art date
Application number
PE2023000303A
Other languages
English (en)
Inventor
Jiacheng Zhou
Shili Chen
Pingli Liu
David J Meloni
Yongchun Pan
Naijing Su
Michael Xia
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PE20231308A1 publication Critical patent/PE20231308A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Health & Medical Sciences (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)

Abstract

Referido a procesos para preparar itacitinib, o una sal de este, que comprende hacer reaccionar un compuesto de formula 3 o una sal de este con un reactivo que se selecciona de: (i) una sal de formula 2a, o una sal de este, y (ii) un compuesto con la formula 2b; en el que X- es un contraanion. En donde el itacitinib y sus sales son inhibidores selectivos de JAK1. Tambien se refiere a sus compuestos intermedios, y el uso de este en el tratamiento de enfermedades inflamatorias, trastornos mieloproliferativos y otras enfermedades.
PE2023000303A 2020-08-18 2021-08-17 Proceso e intermedios para preparar un inhibidor de jak1 PE20231308A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063067062P 2020-08-18 2020-08-18
PCT/US2021/046286 WO2022040172A1 (en) 2020-08-18 2021-08-17 Process and intermediates for preparing a jak1 inhibitor

Publications (1)

Publication Number Publication Date
PE20231308A1 true PE20231308A1 (es) 2023-08-24

Family

ID=77693614

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023000303A PE20231308A1 (es) 2020-08-18 2021-08-17 Proceso e intermedios para preparar un inhibidor de jak1

Country Status (17)

Country Link
US (2) US11897889B2 (es)
EP (1) EP4200278A1 (es)
JP (1) JP7778135B2 (es)
KR (1) KR20230095923A (es)
CN (1) CN117043152A (es)
AR (1) AR123268A1 (es)
AU (1) AU2021329301A1 (es)
BR (1) BR112023002939A2 (es)
CA (1) CA3192055A1 (es)
CL (2) CL2023000482A1 (es)
CO (1) CO2023003286A2 (es)
CR (1) CR20230130A (es)
EC (1) ECSP23019419A (es)
IL (1) IL300557A (es)
MX (1) MX2023002035A (es)
PE (1) PE20231308A1 (es)
WO (1) WO2022040172A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
AU2021329301A1 (en) 2020-08-18 2023-04-13 Incyte Corporation Process and intermediates for preparing a JAK1 inhibitor
MX2023002037A (es) 2020-08-18 2023-06-12 Incyte Corp Proceso e intermediarios para preparar un inhibidor de las cinasas de janus (jak).
US12071439B2 (en) 2021-07-12 2024-08-27 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
WO2024193496A1 (zh) * 2023-03-17 2024-09-26 北京普祺医药科技股份有限公司 吡咯并嘧啶化合物或其可药用盐的制备方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB812366A (en) 1955-08-18 1959-04-22 Wellcome Found Improvements in and relating to derivatives of pyrimidine and the preparation thereof
US5102904A (en) 1989-12-08 1992-04-07 American Cyanamid Company N-oxygenated arylpyrrole insecticidal, acaricidal and nematicidal agents and use thereas
WO2003013518A1 (en) * 2001-08-03 2003-02-20 Smithkline Beecham Corporation Alpha-ketoamide derivatives as cathepsin k inhibitors
EP1551410A2 (en) 2002-09-06 2005-07-13 Smithkline Beecham Corporation Novel compounds
WO2005116035A1 (en) 2004-05-27 2005-12-08 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
RU2384583C2 (ru) 2005-07-29 2010-03-20 Пфайзер Продактс Инк. ПИРРОЛО[2,3-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ И СИНТЕЗ
ATE525374T1 (de) 2005-12-13 2011-10-15 Incyte Corp Heteroarylsubstituierte pyrroloä2,3-büpyridine und pyrroloä2,3-büpyrimidine als januskinaseinhibitoren
CN2928286Y (zh) 2006-01-06 2007-08-01 水城钢铁（集团）有限责任公司 预入口导卫装置
KR101450533B1 (ko) 2006-02-02 2014-10-16 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ１ 활성화 효소의 억제제
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
ES2467665T5 (es) 2007-06-13 2022-11-03 Incyte Holdings Corp Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
EA201000113A1 (ru) 2007-08-01 2010-08-30 Пфайзер Инк. Пиразольные соединения
JP5480813B2 (ja) 2007-11-16 2014-04-23 インサイト・コーポレイション Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
SG191660A1 (en) 2008-03-11 2013-07-31 Incyte Corp Azetidine and cyclobutane derivatives as jak inhibitors
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
WO2010116282A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. 4, 5-dihydro-lh-pyrazole compounds and their pharmaceutical uses
JP6172939B2 (ja) 2009-05-22 2017-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害薬としての３−［４−（７ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）−１ｈ−ピラゾール−１−イル］オクタン−またはヘプタン−ニトリル
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR101805936B1 (ko) 2009-10-09 2017-12-07 인사이트 홀딩스 코포레이션 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
SG10201407129SA (en) 2009-11-06 2014-12-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
MX2012005827A (es) 2009-11-18 2012-06-19 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
BR112012020693B1 (pt) 2010-02-18 2020-05-12 Incyte Holdings Corporation Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende
PE20130038A1 (es) 2010-03-10 2013-01-28 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de jak1
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
KR102303885B1 (ko) 2010-05-21 2021-09-24 인사이트 홀딩스 코포레이션 Ｊａｋ 저해제에 대한 국소 제형
EA026201B1 (ru) 2010-11-19 2017-03-31 Инсайт Холдингс Корпорейшн Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2839767A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
CN105001226B (zh) * 2011-08-12 2017-09-08 日产化学工业株式会社 三环杂环化合物和jak抑制剂
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
EP2628730B1 (en) 2012-02-16 2017-12-06 Noxell Corporation Telescoping synthesis of 5-amino-4-nitroso-1-alkyl-1h-pyrazole salts
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
RS62329B1 (sr) 2012-11-15 2021-10-29 Incyte Holdings Corp Dozni oblici ruksolitiniba sa produženim vremenom oslobađanja
CN103044286B (zh) * 2013-01-25 2015-04-08 重庆紫光化工股份有限公司 丙二腈的合成方法
TR201820520T4 (tr) * 2013-03-06 2019-01-21 Incyte Holdings Corp Bir jak inhibitörü yapmaya yönelik prosesler ve ara ürünler.
PT4275756T (pt) 2013-05-17 2025-10-31 Incyte Holdings Corp Derivados de bipirazole como inibidores da jak
DK3030227T3 (da) 2013-08-07 2020-04-20 Incyte Corp Vedvarende frigivelses-doseringsformer for en jak1-inhibitor
MA39987A (fr) 2014-04-30 2017-03-08 Incyte Corp Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
ES2874537T3 (es) 2014-08-21 2021-11-05 Ratiopharm Gmbh Sal oxalato de ruxolitinib
WO2016026975A1 (en) 2014-08-21 2016-02-25 Ratiopharm Gmbh Salt of (r)-3-(4-(7h-pyrrolo [2,3-d] pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid
WO2016035014A1 (en) 2014-09-01 2016-03-10 Sun Pharmaceutical Industries Limited Processes for the preparation of ruxolitinib phosphate
WO2016063294A2 (en) 2014-10-20 2016-04-28 Msn Laboratories Private Limited Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof
JP6038111B2 (ja) * 2014-12-27 2016-12-07 ヤマサ醤油株式会社 多置換７−デアザプリン誘導体合成のための２，６−ジクロロ−８−ヨード−７−デアザプリン
SG11201706050WA (en) 2015-02-24 2017-09-28 Pfizer Substituted nucleoside derivatives useful as anticancer agents
CA2928286A1 (en) 2015-04-28 2016-10-28 Signa S.A. De C.V. Solid form of ruxolitinib phosphate
CN106397443A (zh) 2015-07-17 2017-02-15 浙江九洲药业股份有限公司 一种吡咯嘧啶类衍生物中间体的制备方法
CZ2015575A3 (cs) 2015-08-26 2017-03-08 Zentiva, K.S. Soli 5-fluoro-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4-onu a jejich příprava
ES2954596T3 (es) 2015-12-23 2023-11-23 Univ British Columbia Profármacos unidos a lípidos
ES2882118T3 (es) 2015-12-31 2021-12-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd Procedimiento de síntesis de ruxolitinib
CZ201629A3 (cs) 2016-01-22 2017-08-02 Zentiva, K.S. Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy
CN107513069A (zh) 2016-06-16 2017-12-26 正大天晴药业集团股份有限公司 手性吡咯并嘧啶化合物的制备方法
IN201641026603A (es) 2016-08-04 2018-02-09
CN107722012B (zh) 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法
CN107759623B (zh) 2016-08-23 2020-08-14 苏州旺山旺水生物医药有限公司 Jak抑制剂的中间体及其制备方法
CN107759601B (zh) 2016-08-23 2020-09-11 苏州旺山旺水生物医药有限公司 一种jak抑制剂及其盐的制备方法
WO2018055097A1 (en) 2016-09-23 2018-03-29 Cellipse Lim kinase inhibitors, pharmaceutical composition and method of use in limk-mediated diseases
CN109651424B (zh) 2017-10-11 2021-01-22 新发药业有限公司 一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法
CN113149993A (zh) * 2017-12-01 2021-07-23 北京普祺医药科技有限公司 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
FI3797099T3 (fi) 2018-05-21 2024-01-30 Pi Industries Ltd Menetelmä substituoitujen heterosyklisten yhdisteiden valmistamiseksi
CN113906032A (zh) 2019-02-06 2022-01-07 康塞特医药品有限公司 用于制备对映异构体富集的jak抑制剂的方法
CN110724145A (zh) 2019-11-01 2020-01-24 廖文杰 一种医药中间体4-氯吡咯并嘧啶的合成方法
CN116761792A (zh) * 2020-08-18 2023-09-15 因赛特公司 用于制备jak抑制剂的方法和中间体
MX2023002037A (es) 2020-08-18 2023-06-12 Incyte Corp Proceso e intermediarios para preparar un inhibidor de las cinasas de janus (jak).
AU2021329301A1 (en) 2020-08-18 2023-04-13 Incyte Corporation Process and intermediates for preparing a JAK1 inhibitor
US12071439B2 (en) 2021-07-12 2024-08-27 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
CN113480546A (zh) 2021-07-30 2021-10-08 江苏君若药业有限公司 巴瑞克替尼及其衍生物的制备

Also Published As

Publication number Publication date
CA3192055A1 (en) 2022-02-24
MX2023002035A (es) 2023-06-12
CL2023000482A1 (es) 2023-09-29
US20240246982A1 (en) 2024-07-25
CN117043152A (zh) 2023-11-10
AU2021329301A1 (en) 2023-04-13
ECSP23019419A (es) 2023-04-28
IL300557A (en) 2023-04-01
EP4200278A1 (en) 2023-06-28
AR123268A1 (es) 2022-11-16
US20220056034A1 (en) 2022-02-24
KR20230095923A (ko) 2023-06-29
CL2024003156A1 (es) 2025-02-28
CO2023003286A2 (es) 2023-06-09
US12428426B2 (en) 2025-09-30
US11897889B2 (en) 2024-02-13
WO2022040172A1 (en) 2022-02-24
BR112023002939A2 (pt) 2023-04-25
CR20230130A (es) 2023-07-13
JP2023538614A (ja) 2023-09-08
TW202212341A (zh) 2022-04-01
JP7778135B2 (ja) 2025-12-01

Similar Documents

Publication Publication Date Title
PE20231308A1 (es) Proceso e intermedios para preparar un inhibidor de jak1
ECSP22042309A (es) Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
AR039789A1 (es) Pirazolopiridinas sustituidas con carbamato
AR057874A1 (es) Aminopirimidinas utiles como inhibidores de quinasa
AR048741A1 (es) Derivados de omega-carboxiaril difenil urea sustituida
DOP2010000148A (es) Derivados bis-(sulfonilzmino) en terapia 066
DOP2010000191A (es) Derivados bis-(sulfonilamino)
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
UY39832A (es) Inhibidores de cdk2
PA8680701A1 (es) Derivados de oxindol
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
AR060873A1 (es) Derivados biciclicos como inhibidores de cetp
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
PE20250667A1 (es) Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2
CL2023003758A1 (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
MX2023014466A (es) Derivados de piridopirimidina útiles como inhibidores de cinasa wee1.
CL2025000445A1 (es) Inhibidores de kif18a y usos de estos
CL2024003171A1 (es) Gamma-hidroxibutirato que administra compuestos y procesos para su fabricación y uso
AR051796A1 (es) Derivados de hidantoina como inhibidores de metaloproteinasas
CL2022003008A1 (es) Procesos para la preparación de un inhibidor de cinasa
ECSP22046595A (es) Procesos e intermediario para la preparaci?n de oxetan-2-ilmetanamina
UY27324A1 (es) Nuevas sales de napsilato i
CL2024002500A1 (es) Inhibidores de proteínas de unión a emopamilo y usos de estos
MX2023014302A (es) Formas cristalinas, composiciones que contienen las mismas y métodos para su uso.
AR133224A1 (es) Inhibidor de sarm1